Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CCCC

CCCC - C4 Therapeutics Inc Stock Price, Fair Value and News

4.38USD-0.43 (-8.94%)Market Closed

Market Summary

CCCC
USD4.38-0.43
Market Closed
-8.94%

CCCC Stock Price

View Fullscreen

CCCC RSI Chart

CCCC Valuation

Market Cap

331.0M

Price/Earnings (Trailing)

-2.63

Price/Sales (Trailing)

15.25

EV/EBITDA

-1.99

Price/Free Cashflow

-3.56

CCCC Price/Sales (Trailing)

CCCC Profitability

EBT Margin

-569.63%

Return on Equity

-48.81%

Return on Assets

-31.65%

Free Cashflow Yield

-28.09%

CCCC Fundamentals

CCCC Revenue

Revenue (TTM)

21.7M

Rev. Growth (Yr)

87.83%

Rev. Growth (Qtr)

-6.21%

CCCC Earnings

Earnings (TTM)

-126.1M

Earnings Growth (Yr)

18.46%

Earnings Growth (Qtr)

18.4%

Breaking Down CCCC Revenue

Last 7 days

2.1%

Last 30 days

-19.7%

Last 90 days

-46.0%

Trailing 12 Months

35.0%

How does CCCC drawdown profile look like?

CCCC Financial Health

Current Ratio

5.08

CCCC Investor Care

Shares Dilution (1Y)

40.24%

Diluted EPS (TTM)

-2.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202421.7M000
202325.5M14.3M18.6M19.9M
202246.0M50.1M48.3M31.1M
202133.8M33.9M34.0M45.8M
202024.3M27.3M30.2M33.2M
201900021.4M

Tracking the Latest Insider Buys and Sells of C4 Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
anderson kenneth carl
acquired
11,250
8.1
1,389
-
Apr 01, 2024
grogan donna roy
acquired
13,745
8.1
1,697
-
Apr 01, 2024
dubin glenn
acquired
10,999
8.1
1,358
-
Feb 15, 2024
hirsch andrew
sold (taxes)
-51,824
7.9
-6,560
president & ceo
Feb 14, 2024
mossler mark
acquired
-
-
18,290
chief accounting officer
Feb 14, 2024
adams kendra
acquired
-
-
36,700
chief financial officer
Feb 14, 2024
reyno leonard
acquired
-
-
36,700
chief medical officer
Feb 14, 2024
siegel jolie
acquired
-
-
27,300
chief legal officer
Feb 14, 2024
boyle scott n
acquired
-
-
27,300
chief business officer
Feb 14, 2024
fisher stewart
acquired
-
-
27,300
chief scientific officer

1–10 of 50

Which funds bought or sold CCCC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
228,760
228,760
-%
May 16, 2024
Arete Wealth Advisors, LLC
added
18.17
288,719
696,084
0.06%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-72.76
-680,380
442,111
-%
May 15, 2024
Point72 Asset Management, L.P.
reduced
-53.78
-3,675,800
7,405,880
0.02%
May 15, 2024
Lynx1 Capital Management LP
added
15.96
11,985,900
29,695,200
7.65%
May 15, 2024
STATE STREET CORP
added
4,503
57,564,400
58,442,300
-%
May 15, 2024
WELLINGTON MANAGEMENT GROUP LLP
new
-
1,610,380
1,610,380
-%
May 15, 2024
MORGAN STANLEY
added
150
3,040,700
4,200,880
-%
May 15, 2024
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-567,090
-
-%
May 15, 2024
HSBC HOLDINGS PLC
sold off
-100
-170,630
-
-%

1–10 of 45

Are Funds Buying or Selling CCCC?

Are funds buying CCCC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CCCC
No. of Funds

Unveiling C4 Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
state street corp
10.43%
7,153,280
SC 13G
Mar 08, 2024
wasatch advisors lp
-
0
SC 13G/A
Feb 14, 2024
lynx1 capital management lp
6.4%
3,134,396
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
5.2%
2,558,480
SC 13G/A
Feb 14, 2024
rtw investments, lp
0%
0
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Feb 05, 2024
soleus capital master fund, l.p.
5.2%
2,555,996
SC 13G
Feb 02, 2024
soleus capital master fund, l.p.
3.7%
1,835,996
SC 13G/A
Jan 12, 2024
betta investment (hong kong) ltd.
8.1%
5,567,928
SC 13G
Jan 04, 2024
point72 asset management, l.p.
4.7%
2,312,059
SC 13G

Recent SEC filings of C4 Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
3
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
8-K
Current Report
May 08, 2024
10-Q
Quarterly Report
May 08, 2024
8-K
Current Report
Apr 30, 2024
ARS
ARS
Apr 29, 2024
DEF 14A
DEF 14A
Apr 29, 2024
DEFA14A
DEFA14A
Apr 10, 2024
SC 13G
Major Ownership Report
Apr 10, 2024
4
Insider Trading

Peers (Alternatives to C4 Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
13.11% 15.14%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.19% -19.39%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
5.74% -10.79%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
9.90% 2.05%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
0.17% 71.70%
-9.53
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.5B
251.0M
-6.27% -10.41%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
15.67% -25.01%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.65% 94.95%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
22.84% 567.64%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-17.34% 57.33%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

C4 Therapeutics Inc News

Latest updates
Yahoo Finance13 hours ago

C4 Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Revenue-6.2%3,858,0004,113,50011,072,0002,664,0002,054,0002,854,0006,754,00013,834,0007,654,00020,078,0008,500,0009,781,0007,426,0008,262,0008,447,0009,670,0006,816,0006,090,0005,364,000
Operating Expenses-13.3%35,258,00040,688,00038,880,00040,232,00039,987,00041,147,00039,242,00041,218,00039,023,00035,333,00032,754,00031,897,00027,935,00027,165,00026,796,00020,529,00019,154,000-15,365,000
  S&GA Expenses-0.1%10,288,00010,297,00010,533,00010,306,00010,945,00010,495,0009,579,0009,895,00012,820,0008,782,0008,452,0008,611,0007,409,0006,732,0002,861,0002,769,0002,842,000-2,417,000
  R&D Expenses-25.9%22,533,00030,391,00028,347,00029,926,00029,042,00030,652,00029,663,00031,323,00026,203,00026,551,00024,302,00023,286,00020,526,00020,433,00023,935,00017,760,00016,312,000-12,948,000
EBITDA Margin14.2%-5.59-6.51-6.22-8.23-4.86-3.64-2.09-1.83-1.99-1.77-2.58-2.51-------
Interest Expenses---138,000422,000430,000421,000375,000355,000473,000238,000363,000349,000358,000------
Income Taxes-100.0%-277,0001,003,000-----------124,000-167,000-168,000-167,000-650,000
Earnings Before Taxes17.7%-28,361,000-34,477,000-26,034,000--34,780,000-37,185,000-31,958,000--31,620,000-15,658,000-24,683,000-22,580,000-20,971,000-21,919,000-22,002,000-10,961,000-12,079,000--9,444,000
EBT Margin14.4%-5.70-6.66-6.39-8.46-4.98-3.74-2.15-1.89-2.05-1.83-2.65-2.58-------
Net Income18.4%-28,361,000-34,754,000-27,037,000-35,922,000-34,780,000-37,185,000-31,958,000-27,412,000-31,620,000-15,658,000-24,683,000-22,580,000-20,971,000-21,795,000-21,835,000-10,793,000-11,912,000--10,094,000
Net Income Margin12.8%-5.81-6.66-6.63-8.72-4.83-4.12-2.21-1.98-2.05-1.83-2.65-2.57-------
Free Cashflow25.0%-18,118,000-24,166,000-31,307,000-19,359,000-33,714,000-30,618,000-31,325,000-22,724,000-26,768,000-25,780,000-18,358,000-18,749,000-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets5.8%398376333375396431461492515507508528374400229118
  Current Assets3.1%28027122427427828832531830332641247832238120997.00
    Cash Equivalents-29.2%90.0012761.0045.0049.0033.0050.0057.0046.0079.0016328195.0018463.0091.00
  Net PPE-5.3%7.007.007.008.008.007.007.006.003.003.003.004.004.003.004.004.00
Liabilities7.5%140130117141134142143148151117109112110119129119
  Current Liabilities28.6%55.0043.0030.0048.0039.0045.0045.0046.0047.0051.0049.0044.0038.0044.0040.0034.00
  Long Term Debt-----9.009.009.0010.0010.0011.0011.0010.0010.0010.0010.00-
    LT Debt, Current----10.002.002.002.001.001.00-------
    LT Debt, Non Current-----9.009.009.0010.0010.0011.0011.0010.0010.0010.0010.00-
Shareholder's Equity4.9%258246216234262289318345365390399416264281--
  Retained Earnings-5.4%-556-528-493-466-430-395-358-326-299-267-252-227-204-183-162-117
  Additional Paid-In Capital5.3%8157757117026966896826766686586516444694656.006.00
Shares Outstanding13.7%69.0060.0049.0049.0049.0049.0049.0049.0049.0049.0045.0043.00----
Float----130---201---1,278----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations24.5%-18,118-24,009-30,707-18,997-33,125-29,128-28,020-22,195-26,596-25,671-18,358-18,002-24,934-21,593-14,396-14,594-16,666--
  Share Based Compensation-2.3%6,2156,3598,2006,4256,2516,9196,0118,1488,9386,3536,0865,2283,8452,719436161116--
Cashflow From Investing-267.1%-53,39631,94557,72515,14853,5319,28419,91433,228-4,004-59,413-100,62732,434-61,730-54,167-32,321-103,833-184--
Cashflow From Financing-40.0%34,58357,672-10,753-746-68447.00361259480466584170,501-151194,0532,499152,224156--
  Buy Backs-109-16.00-94.00---------16.0086.00-78.00202-6.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CCCC Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue from collaboration agreements$ 3,039$ 3,759
Operating expenses:  
Research and development22,53329,042
General and administrative10,28810,945
Restructuring2,4370
Total operating expenses35,25839,987
Loss from operations(32,219)(36,228)
Other income (expense), net:  
Interest expense and amortization of long-term debt − related party0(606)
Interest and other income, net3,8582,054
Total other income (expense), net3,8581,448
Loss before income taxes(28,361)(34,780)
Income tax expense00
Net loss$ (28,361)$ (34,780)
Net loss per share − basic (in dollars per share)$ (0.41)$ (0.71)
Net loss per share − diluted (in dollars per share)$ (0.41)$ (0.71)
Weighted-average number of shares used in computed net loss per share − basic68,432,16849,032,319
Weighted-average number of shares used in computed net loss per share − diluted68,432,16849,032,319
Other comprehensive income (loss)  
Unrealized (loss) gain on marketable securities$ (253)$ 1,667
Comprehensive loss$ (28,614)$ (33,113)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Collaborative Arrangement [Member]Collaborative Arrangement [Member]

CCCC Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 89,659$ 126,590
Marketable securities, current168,533127,091
Accounts receivable13,59911,799
Prepaid expenses and other current assets7,8015,709
Total current assets279,592271,189
Marketable securities, non-current40,97528,008
Property and equipment, net6,7567,132
Right-of-use asset62,37763,956
Restricted cash3,4433,443
Other assets5,2282,723
Total assets398,371376,451
Current liabilities:  
Accounts payable1,6301,446
Accrued expenses and other current liabilities12,89120,630
Deferred revenue, current35,14215,471
Operating lease liability, current5,3555,219
Total current liabilities55,01842,766
Deferred revenue, net of current20,70621,814
Operating lease liability, net of current64,36565,757
Total liabilities140,089130,337
Commitments and contingencies (see Note 11)
Stockholders’ equity:  
Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of March 31, 2024 and December 31, 2023, respectively00
Common stock, par value of $0.0001 per share; 150,000,000 shares authorized, and 68,778,591 and 60,467,188 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively76
Additional paid-in capital815,399774,618
Accumulated other comprehensive loss(380)(127)
Accumulated deficit(556,744)(528,383)
Total stockholders’ equity258,282246,114
Total liabilities and stockholders’ equity$ 398,371$ 376,451
CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEc4therapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES146

C4 Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for C4 Therapeutics Inc? What does CCCC stand for in stocks?

CCCC is the stock ticker symbol of C4 Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of C4 Therapeutics Inc (CCCC)?

As of Thu Jun 13 2024, market cap of C4 Therapeutics Inc is 330.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CCCC stock?

You can check CCCC's fair value in chart for subscribers.

What is the fair value of CCCC stock?

You can check CCCC's fair value in chart for subscribers. The fair value of C4 Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of C4 Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CCCC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is C4 Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CCCC is over valued or under valued. Whether C4 Therapeutics Inc is cheap or expensive depends on the assumptions which impact C4 Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CCCC.

What is C4 Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, CCCC's PE ratio (Price to Earnings) is -2.63 and Price to Sales (PS) ratio is 15.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CCCC PE ratio will change depending on the future growth rate expectations of investors.